Progress of relapse after allogeneic hematopoietic stem cell transplantation
10.3760/cma.j.issn.1009-9921.2019.01.005
- VernacularTitle:异基因造血干细胞移植后复发研究进展
- Author:
Siqi LI
1
;
Yingjun CHANG
Author Information
1. 北京大学人民医院 北京大学血液病研究所 造血干细胞移植治疗血液病北京市重点实验室 100044
- Keywords:
Hematologic neoplasms;
Hematopoietic stem cell transplantation;
Recurrence;
Chimeric antigen receptor T-cell;
Indication
- From:
Journal of Leukemia & Lymphoma
2019;28(1):17-20
- CountryChina
- Language:Chinese
-
Abstract:
Hematologic neoplasm relapse remains one of the major causes of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Relaspe prediction, prophylaxis and treatment after allo-HSCT are the key issues for improving the therapeutic effects and prognosis. This paper chooses some representative reports from 60th American Society of Hematology (ASH) Annual Meeting to discuss the progress of allo-HSCT.
